A single point mutation in framework region 3 of heavy chain affects viral neutralization dynamics of single-chain Fv against bovine herpes virus type 1

Vaccine

Volumn 29, Issue 45, 2011, Pages 7905-7912

  Koti, Madhuri ^a   Nagy, Eva ^a   Kaushik, Azad K ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Antibody; Bovine herpes virus 1; Single chain fragment variable; Virus neutralization

Indexed keywords

SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS ANTIGEN;

ARTICLE; BOVINE HERPES VIRUS; CONTROLLED STUDY; GENE EXPRESSION; HEAVY CHAIN; IMMUNOFLUORESCENCE; MOLECULAR DYNAMICS; NONHUMAN; POINT MUTATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CATTLE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HERPESVIRUS 1, BOVINE; IMMUNOLOGIC TESTS; IMMUNOTHERAPY; MUTANT PROTEINS; MUTATION, MISSENSE; NEUTRALIZATION TESTS; POINT MUTATION; SINGLE-CHAIN ANTIBODIES;

EID: 80053631719     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.077     Document Type: Article

References (58)

1. Tonegawa S. Somatic generation of antibody diversity. Nature 1983, 3023(April (5909)):575-581.
2. Klee G.G. Human anti-mouse antibodies. Arch Pathol Lab Med 2000, 124(June (6)):921-923.
3. Morrison S.L, Johnson M.J., Herzenberg L.A., Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984, 81(November (21)):6851-6855.
4. Boulianne G.L., Hozumi N., Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 1984, 312(December (5995)):643-646.
5. Knight K.L., Suter M., Becker R.S. Genetic engineering of bovine Ig. Construction and characterization of hapten-binding bovine/murine chimeric IgE, IgA, IgG1, IgG2, and IgG3 molecules. J Immunol 1988, 140(May (10)):3654-3659.
6. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321(May-June (6069)):522-525.
7. Co M.S., Queen C. Humanized antibodies for therapy. Nature 1991, 351(June (6326)):501-502.
8. Winter G., Harris W.J. Humanized antibodies. Immunol Today 1993, 14(June (6)):243-246.
9. Rader C., Cheresh D.A., Barbas C.F. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci USA 1998, 95(July (15)):8910-8915.
10. Barbas C.F., Kang A.S., Lerner R.A., Benkovic S.J. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci USA 1991, 88(September (18)):7978-7982.
11. Glockshuber R., Malia M., Pfitzinger I., Pluckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990, 29(February (6)):1362-1367.
12. FitzGerald K., Holliger P., Winter G. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997, 10(October (10)):1221-1225.
13. Colcher D., Bird R., Roselli M., Hardman K.D., Johnson S., Pope S., et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 1990, 82(July (14)):1191-1197.
14. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992, 52(June (12)):3402-3408.
15. Adams G.P., Schier R., McCall A.M., Crawford R.S., Wolf E.J., Weiner L.M., et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998, 77(May (9)):1405-1412.
16. Beck A., Wurch T., Bailly C., Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010, 10(May (5)):345-352.
17. Dubel S. Handbook of therapeutic antibodies: technologies, emerging developments and approved therapeutics 2009, Wiley-Blackwell.
18. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005, 23(September (9)):1126-1136.
19. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010, 10(May (5)):301-316.
20. ShengFeng C., Ping L., Tao S., Xin W., GuoFeng W. Construction, expression, purification, refold and activity assay of a specific scFv fragment against foot and mouth disease virus. Vet Res Commun 2003, 27(April (3)):243-256.
21. Cardinale A., Filesi I., Vetrugno V., Pocchiari M., Sy M.S., Biocca S. Trapping prion protein in the endoplasmic reticulum impairs PrPC maturation and prevents PrPSc accumulation. J Biol Chem 2005, 280(January (1)):685-694.
22. Donofrio G., Heppner F.L., Polymenidou M., Musahl C., Aguzzi A. Paracrine inhibition of prion propagation by anti-PrP single-chain Fv miniantibodies. J Virol 2005, 79(July (13)):8330-8338.
23. Padiolleau-Lefevre S., Alexandrenne C., Dkhissi F., Clement G., Essono S., Blache C., et al. Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: implications for therapeutic use in prion diseases. Mol Immunol 2007, 44(March (8)):1888-1896.
24. Koti M., Farrugia W., Nagy E., Ramsland P.A., Kaushik A.K. Construction of single-chain Fv with two possible CDR3H conformations but similar inter-molecular forces that neutralize bovine herpesvirus 1. Mol Immunol 2010, 47(February (5)):953-960.
25. Tschopp J.F., Brust P.F., Cregg J.M., Stillman C.A., Gingeras T.R. Expression of the lacZ gene from two methanol-regulated promoters in Pichia pastoris. Nucleic Acids Res 1987, 15(May (9)):3859-3876.
26. Cregg J.M., Madden K.R., Barringer K.J., Thill G.P., Stillman C.A. Functional characterization of the two alcohol oxidase genes from the yeast Pichia pastoris. Mol Cell Biol 1989, 9(March (3)):1316-1323.
27. Cereghino G.P., Cereghino J.L., Ilgen C., Cregg J.M. Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris. Curr Opin Biotechnol 2002, 13(August (4)):329-332.
28. Huston J.S., Tai M.S., McCartney J., Keck P., Oppermann H. Antigen recognition and targeted delivery by the single-chain Fv. Cell Biophys 1993, 22(January-June (1-3)):189-224.
29. Borrebaeck C.A. Antibody engineering 1994, Oxford University Press, USA. 2nd ed.
30. Freund C., Ross A., Guth B., Pluckthun A., Holak T.A. Characterization of the linker peptide of the single-chain Fv fragment of an antibody by NMR spectroscopy. FEBS Lett 1993, 320(April (2)):97-100.
31. Freund C., Ross A., Pluckthun A., Holak T.A. Structural and dynamic properties of the Fv fragment and the single-chain Fv fragment of an antibody in solution investigated by heteronuclear three-dimensional NMR spectroscopy. Biochemistry 1994, 33(March (11)):3296-3303.
32. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., et al. Single-chain antigen-binding proteins. Science 1988, 242(October (4877)):423-426.
33. Whitlow M., Bell B.A., Feng S.L., Filpula D., Hardman K.D., Hubert S.L., et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 1993, 6(November (8)):989-995.
34. Kortt A.A., Malby R.L., Caldwell J.B., Gruen L.C., Ivancic N., Lawrence M.C., et al. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. Eur J Biochem 1994, 221(April (1)):151-157.
35. Perisic O., Webb P.A., Holliger P., Winter G., Williams R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994, 2(December (12)):1217-1226.
36. Levings RL, Stoll IR, inventor. Bovine monoclonal antibodies to bovine herpesvirus 1 from sequential fusion heterohybridomas. U.S.A.; 1991.
37. Saini S.S., Allore B., Jacobs R.M., Kaushik A. Exceptionally long CDR3H region with multiple cysteine residues in functional bovine IgM antibodies. Eur J Immunol 1999, 29(August (8)):2420-2426.
38. Saini S.S., Hein W.R., Kaushik A. A single predominantly expressed polymorphic immunoglobulin VH gene family, related to mammalian group, I, clan, II, is identified in cattle. Mol Immunol 1997, 34(June (8-9)):641-651.
39. Lefranc M.P., Pommie C., Ruiz M., Giudicelli V., Foulquier E., Truong L., et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003, 27(January (1)):55-77.
40. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227(August (5259)):680-685.
41. Silva S.V., Little P.B., Kaushik A. An immunodominant epitope on 40 kilodalton outer membrane protein is conserved among different strains of Haemophilus (Histophilus) somnus. Zentralbl Bakteriol 1995, 282(October (4)):449-456.
42. Martin S.W., Nagy E., Armstrong D., Rosendal S. The associations of viral and mycoplasmal antibody titers with respiratory disease and weight gain in feedlot calves. Can Vet J 1999, 40(August (8)):560-567. 70.
43. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol 2006, 6(May (5)):343-357.
44. Boder E.T., Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997, 15(June (6)):553-557.
45. Sinclair M.C., Gilchrist J., Aitken R. Molecular characterization of bovine V lambda regions. J Immunol 1995, 155(September (6)):3068-3078.
46. Saini S.S., Farrugia W., Ramsland P.A., Kaushik A.K. Bovine IgM antibodies with exceptionally long complementarity-determining region 3 of the heavy chain share unique structural properties conferring restricted VH+Vlambda pairings. Int Immunol 2003, 15(July (7)):845-853.
47. Olafsen T., Cheung C.W., Yazaki P.J., Li L., Sundaresan G., Gambhir S.S., et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 2004, 17(January (1)):21-27.
48. Cochlovius B., Kipriyanov S.M., Stassar M.J., Schuhmacher J., Benner A., Moldenhauer G., et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3×CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000, 60(August (16)):4336-4341.
49. Turner D.J., Ritter M.A., George A.J. Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology. J Immunol Methods 1997, 205(June (1)):43-54.
50. Dall'Acqua W., Carter P. Antibody engineering. Curr Opin Struct Biol 1998, 8(August (4)):443-450.
51. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA 1988, 85(August (16)):5879-5883.
52. Kortt A.A., Lah M., Oddie G.W., Gruen C.L., Burns J.E., Pearce L.A., et al. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng 1997, 10(April (4)):423-433.
53. Arndt K.M., Muller K.M., Pluckthun A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry 1998, 37(September (37)):12918-12926.
54. Atwell J.L., Breheney K.A., Lawrence L.J., McCoy A.J., Kortt A.A., Hudson P.J. scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies. Protein Eng 1999, 12(July (7)):597-604.
55. Desplancq D., King D.J., Lawson A.D., Mountain A. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. Protein Eng 1994, 7(August (8)):1027-1033.
56. Knappik A., Pluckthun A. Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng 1995, 8(January (1)):81-89.
57. Ohlin M., Borrebaeck C.A. Insertions and deletions in hypervariable loops of antibody heavy chains contribute to molecular diversity. Mol Immunol 1998, 35(March (4)):233-238.
58. Krause J.C., Ekiert D.C., Tumpey T.M., Smith P.B., Wilson I.A., Crowe J.E. An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody. MBio 2011, 2(1).